JP2005512515A - 治療ポリペプチド、同一物をコード化する核酸、および使用方法 - Google Patents

治療ポリペプチド、同一物をコード化する核酸、および使用方法 Download PDF

Info

Publication number
JP2005512515A
JP2005512515A JP2003527073A JP2003527073A JP2005512515A JP 2005512515 A JP2005512515 A JP 2005512515A JP 2003527073 A JP2003527073 A JP 2003527073A JP 2003527073 A JP2003527073 A JP 2003527073A JP 2005512515 A JP2005512515 A JP 2005512515A
Authority
JP
Japan
Prior art keywords
novx
polypeptide
nucleic acid
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003527073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512515A5 (enExample
Inventor
メイ・ジョン
リ・リ
リンダ・ゴーマン
キンバリー・エイ・スピテック
ラメシュ・ケクダ
レイモンド・ジェイ・トーピアー・ジュニア
デイビッド・ダブリュー・アンダーソン
コリーヌ・ア・エム・ヴェルネ
エリナ・カッテルトン
チャールズ・イー・ミラー
スレシュ・ジー・シェノイ
メーラ・パトゥラジャン
キャロル・イー・エイ・ピーナ
ヴェリザル・トゥ・チェルネフ
ムラリダラ・パディガル
ウラディミール・ウー・グセフ
ウリエル・エム・マルヤンカル
キャサリン・イー・バージェス
バレリー・エル・ガーラッチ
ステイシー・ジェイ・キャスマン
ダニエル・カー・リーガー
ウィリアム・エム・グロース
グレンダ・スミスソン
ジョン・エイ・ペイマン
ゲイリー・スターリング
マーク・イー・ローゼンバーグ
ウィリアム・ジェイ・ラロシェル
リチャード・エイ・シムケッツ
ジュリー・クラブツリー
ルカ・ラステッリ
エドワード・ゼット・ボス
フェレンツ・エル・ボルドグ
シュロミット・アール・エディンガー
イザベル・ミレー
ジョン・アール・マクドゥゴール
カレン・エラーマン
アンドレイ・チャポヴァル
Original Assignee
キュラジェン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラジェン コーポレイション filed Critical キュラジェン コーポレイション
Publication of JP2005512515A publication Critical patent/JP2005512515A/ja
Publication of JP2005512515A5 publication Critical patent/JP2005512515A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
JP2003527073A 2001-09-07 2002-09-09 治療ポリペプチド、同一物をコード化する核酸、および使用方法 Pending JP2005512515A (ja)

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US31812001P 2001-09-07 2001-09-07
US31813001P 2001-09-07 2001-09-07
US31821901P 2001-09-07 2001-09-07
US31843001P 2001-09-10 2001-09-10
US31876501P 2001-09-12 2001-09-12
US32278101P 2001-09-17 2001-09-17
US32281601P 2001-09-17 2001-09-17
US32351901P 2001-09-19 2001-09-19
US32363601P 2001-09-20 2001-09-20
US32363101P 2001-09-20 2001-09-20
US32509101P 2001-09-25 2001-09-25
US32496901P 2001-09-25 2001-09-25
US32499001P 2001-09-26 2001-09-26
US35730302P 2002-02-15 2002-02-15
US36097302P 2002-02-28 2002-02-28
US36613102P 2002-03-20 2002-03-20
US36775302P 2002-03-25 2002-03-25
US36947902P 2002-04-02 2002-04-02
US37953202P 2002-05-10 2002-05-10
US38167202P 2002-05-17 2002-05-17
US38166402P 2002-05-17 2002-05-17
US38365102P 2002-05-28 2002-05-28
US38401202P 2002-05-29 2002-05-29
US39015502P 2002-06-19 2002-06-19
US10/236,392 US20040067490A1 (en) 2001-09-07 2002-09-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PCT/US2002/028596 WO2003023008A2 (en) 2001-09-07 2002-09-09 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Publications (2)

Publication Number Publication Date
JP2005512515A true JP2005512515A (ja) 2005-05-12
JP2005512515A5 JP2005512515A5 (enExample) 2006-01-05

Family

ID=32046248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003527073A Pending JP2005512515A (ja) 2001-09-07 2002-09-09 治療ポリペプチド、同一物をコード化する核酸、および使用方法

Country Status (5)

Country Link
US (1) US20040067490A1 (enExample)
EP (1) EP1576086A2 (enExample)
JP (1) JP2005512515A (enExample)
CA (1) CA2451454A1 (enExample)
WO (1) WO2003023008A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010902A2 (en) * 1999-08-11 2001-02-15 Curagen Corporation Nucleoc acids and secreted polypeptides encoded thereby
FR2820739B1 (fr) 2001-02-13 2004-01-02 Ajinomoto Kk Derive d'acide amine et gelifiant, composition de gel et cosmetique le contenant, et procedes de preparation correspondants
US20030077775A1 (en) * 2001-10-17 2003-04-24 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
JP3955885B2 (ja) * 2002-12-29 2007-08-08 日産化学工業株式会社 アディポネクチン受容体及びそれをコードする遺伝子
EP2902491A1 (en) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO receptor binding protein
WO2004094608A2 (en) * 2003-04-18 2004-11-04 Curagen Corporation Human procolipase like nucleic acids and polypeptides and their methods of use threof
JP2007506951A (ja) 2003-09-27 2007-03-22 バイエル・ヘルスケア・エルエルシー Ｇタンパク質共役受容体ＡｄｉｐｏＲ１（ＡｄｉｐｏＲ１）に関連する疾患の診断および治療
DK1776136T3 (da) 2004-06-24 2012-12-03 Biogen Idec Inc Behandling af tilstande, der involverer demyelinisering
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008091781A1 (en) * 2007-01-22 2008-07-31 Mayo Foundation For Medical Education And Research Reducing tumor growth
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
CN101932728B (zh) 2007-11-30 2013-06-19 西门子医疗保健诊断公司 脂连蛋白受体片段和使用方法
ES2527072T3 (es) 2008-03-19 2015-01-19 China Synthetic Rubber Corporation Procedimientos y agentes para el diagnóstico y el tratamiento de carcinoma hepatocelular
US8058406B2 (en) * 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
EP3199553B1 (en) 2008-10-29 2019-04-24 Circular Commitment Company Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
EP2422199B1 (en) 2009-04-23 2018-07-25 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
JP6401060B2 (ja) * 2012-02-24 2018-10-03 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｓｅｚ６抗体及び使用方法
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
BR112016004242A8 (pt) * 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
US9993566B2 (en) 2013-08-28 2018-06-12 Abbvie Stemcentrx Llc SEZ6 modulators and methods of use
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
HK1246810A1 (zh) 2015-01-08 2018-09-14 Biogen Ma Inc. Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
CA3108731A1 (en) * 2018-08-03 2020-02-06 Scripps Health Detection and isolation of myeloid-derived suppressor cell subpopulations
CN110208276B (zh) * 2019-07-02 2023-03-31 广州越监工程质量安全检测中心有限公司 一种结构砼表观缺陷测定仪及其检测设备
CN120272602B (zh) * 2025-03-20 2025-12-23 江苏省家禽科学研究所 Ston2基因中与开产日龄相关的遗传标记在蛋鸡遗传育种中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5639660A (en) * 1988-02-24 1997-06-17 Hoffmann-La Roche Inc. Polypeptide and DNA sequence corresponding to the human receptor with high affinity for IgE
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
ATE356869T1 (de) * 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) * 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5527679A (en) * 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
US6004924A (en) * 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5233409A (en) * 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
WO1994007906A1 (en) * 1992-10-01 1994-04-14 Board Of Regents, The University Of Texas System Epidermal surface antigen and uses thereof
EP0657811B1 (en) * 1993-12-09 1998-09-02 STMicroelectronics S.r.l. Integrated circuitry for checking the utilization rate of redundancy memory elements in a semiconductor memory device
US5635360A (en) * 1995-03-15 1997-06-03 Becton, Dickinson And Company Immunoassay for human restrictin
US5736866A (en) * 1995-11-13 1998-04-07 Kabushiki Kaisha Toshiba Active pull-down circuit for ECL using a capacitive coupled circuit
US6083693A (en) * 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6326472B1 (en) * 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
WO2001010902A2 (en) * 1999-08-11 2001-02-15 Curagen Corporation Nucleoc acids and secreted polypeptides encoded thereby
US20030211991A1 (en) * 2001-04-17 2003-11-13 Su Eric Wen Human sez6 nucleic acids and polypeptides

Also Published As

Publication number Publication date
WO2003023008A2 (en) 2003-03-20
US20040067490A1 (en) 2004-04-08
EP1576086A2 (en) 2005-09-21
CA2451454A1 (en) 2003-03-20
WO2003023008A8 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
JP2005512515A (ja) 治療ポリペプチド、同一物をコード化する核酸、および使用方法
JP2005518185A (ja) 新規タンパク質およびそれをコード化する核酸
WO2003023008A9 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030199442A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2005528080A (ja) 治療ポリペプチド、同一物をコード化する核酸、および使用方法
JP2005515758A (ja) 新規タンパク質およびそれらをコード化する核酸
EP1432726A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003078572A2 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
JP2006501813A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2006516082A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2005518193A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2005522186A (ja) 新規タンパク質およびそれらをコード化する核酸
JP2005519629A (ja) 治療ポリペプチドとコード化核酸と使用方法
JP2005506054A (ja) 抗原性治療的ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
JP2004533235A (ja) 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法
JP2006509491A (ja) 新規蛋白およびそれらをコードする核酸
JP2005506833A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法
US20030229016A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005507236A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
JP2005528886A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
WO2004089282A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2006507793A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
EP1622634A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2005532786A (ja) 新規蛋白およびそれらをコードする核酸
JP2005518200A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050714

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070807

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080624